Global languages
2008-02-15
Regulatory

CELLAVISION AB (publ) - Year-End Bulletin 2007

January - December
  •    Net sales increased by 36 % to SEK 74.6 million (54.8).
  •    The operating result for the year increased to SEK 3.1 million (-8.6), an improvement of SEK 11.7 million as compared to the previous year. The net result increased to SEK 2.6 million (-8.8).
  •    The net result per share amounted to SEK 0.11 million (-0.37).
  •    Liquid assets amounted to SEK 16.3 million (16.8).
  •    Orders continuously strong on the European market.
  •    New application for body fluids launched in the fall.
  •    An evaluation of a potential future establishment on the Japanese market was initiated.
  •    CellaVision was admitted to trading on First North by the Stockholm Stock Exchange on May 28.
    •  
    October - December
  •    Net sales for the fourth quarter increased by 25 % to SEK 19.4 million (15.5).
  •    The operating result amounted to SEK 3.0 million (-1.3) and the net result per share to SEK 0.12 million (-0.05).
  •    The gross profit increased to 73 % (66).
    •  
    Important events after the reporting period
  •    As of January 1 the agreement with the distributor Sysmex was altered, allowing CellaVision to sell parallel to Sysmex on the American market.
    •  

      CellaVision in short
     
     
     
      (MSEK)
     
    Q4 2007
    Q4 2006
    2007
    2006
      Net sales
    19.4
    15.5
    74.6
    54.8
      Gross profit
    14.1
    10.2
    45.3
    32.0
      Operating result
    3.0
    -1.3
    3.1
    -8.6
      Net result
    2.8
    -1.2
    2.6
    -8.8
      Cash flow
    0.1
    -1.4
    -0.4
      -0.8
     
    CEO's comment
    "It is pleasing to present a positive result for the year and a sales increase of 36 %. A key reason for this is that we further fortified our position on markets where we are already well established, most importantly in Europe. In order to increase the volume of sales in the North American market, in 2008 we will invest in our own organization and sell in parallel to our American distributor. In addition we are evaluating a potential establishment on the Japanese market," says Yvonne Mårtensson, CEO of CellaVision.
     
    "Another milestone for the company was the initiation of trade at First North, which makes us more visible on the financial market. All of this combined makes me hopeful of CellaVision's development during 2008 and the coming years."
     
    For more information please contact:
    Yvonne Mårtensson, CEO. Phone: +46 708 33 77 82, e-mail: yvonne.martensson@cellavision.se 
    Johan Wennerholm, CFO. Phone: +46 708 33 81 68, e-mail: johan.wennerholm@cellavision.se
     

    Attachments

    CellaVision AB (publ) - Year-End Bulletin 2007

    Share